Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms - Summary - MDSpire

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

  • By

  • Christoph J Auernhammer

  • Katharina Wang

  • Umberto Maccio

  • Thomas Knösel

  • Maximilian P Hungbauer

  • Katharina Schilbach

  • Julian Maurer

  • Lea Peischer

  • Astrid Reul

  • Elena Kuzmenko

  • Edlira Luca

  • Julia Hamati

  • Diana Vetter

  • Jose Oberholzer

  • Ralph Fritsch

  • Karel Pacak

  • Ashley B Grossman

  • Felix Beuschlein

  • Martin Reincke

  • Constanze Hantel

  • Kathrin Zitzmann

  • Svenja Nölting

  • January 10, 2026

  • 0 min

Share

Objective:

To evaluate individual tumor responses to various agents in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) using a personalized drug screening and risk assessment platform, which aims to tailor treatment strategies based on specific tumor characteristics.

Key Findings:
  • Statistically significant differences in drug response were observed between pancreatic NETs (pNETs) and small intestinal NETs (siNETs), indicating distinct therapeutic needs.
  • Identified individualized responsiveness and resistance data for various therapies, which could inform personalized treatment plans.
  • Novel data on the efficacy of both established and potential therapies in patient-derived GEP-NEN cultures were provided, highlighting the platform's utility.
Interpretation:

The standardized platform enables prediction of individual tumor treatment responses, addressing the urgent need for personalized therapies in GEP-NENs, potentially leading to improved patient outcomes.

Limitations:
  • Study limited to a small sample size of 23 primary cultures, which may restrict the generalizability of the findings to the broader GEP-NEN patient population.
  • Findings may not be generalizable to all GEP-NEN patients due to the specific characteristics of the sampled tumors.
Conclusion:

This research highlights the potential of personalized drug screening in improving treatment outcomes for patients with GEP-NENs.

Original Source(s)

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

  • by Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting

  • January 10, 2026

Related Content

Growth hormone therapy after hematopoietic cell transplantation in childhood: a nationwide survey and longitudinal cohort study

A serum exosomal four-miRNA signature for the diagnosis of central precocious puberty: a discovery and validation study

Climate Vulnerability and Cardiometabolic Health Among Children